Financials data is unavailable for this security.
View more
Year on year AC Immune SA grew revenues 276.14% from 3.94m to 14.80m while net income improved from a loss of 70.75m to a smaller loss of 54.23m.
Gross margin | -- |
---|---|
Net profit margin | -390.68% |
Operating margin | -387.63% |
Return on assets | -30.73% |
---|---|
Return on equity | -46.06% |
Return on investment | -42.90% |
More ▼
Cash flow in CHFView more
In 2023, AC Immune SA increased its cash reserves by 148.51%, or 46.91m. Cash Flow from Investing totalled 65.65m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 60.41m for operations while cash generated from financing totalled 43.25m.
Cash flow per share | -0.7193 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.42 |
---|---|
Tangible book value per share | 0.8409 |
More ▼
Balance sheet in CHFView more
Current ratio | 1.80 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0262 |
---|---|
Total debt/total capital | 0.0255 |
More ▼
Growth rates in CHF
SmartText is unavailable
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 19.20 |